Shanghai HeartCare Signals Strong 2025 Turnaround With Positive Profit Alert

Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) has provided an announcement.

Shanghai HeartCare Medical Technology Corporation Limited has issued a positive profit alert, indicating that its 2025 revenue is expected to rise to about RMB400–410 million, at least 43.9% higher than 2024, and that it anticipates a profit before tax of roughly RMB80 million, marking a sharp turnaround from a pre-tax loss of RMB12 million a year earlier. The improvement is driven by robust sales momentum from newly launched ischemic stroke products, scaled commercialization of intracranial stents and other hemorrhagic stroke devices, continued growth in interventional access products, and tighter cost controls that have lowered the expense ratio; on an adjusted non-IFRS basis, the company also expects to swing from an adjusted pre-tax loss to an adjusted pre-tax profit of around RMB77 million, underscoring a significant enhancement in underlying operating performance, although the figures remain preliminary and unaudited.

The most recent analyst rating on (HK:6609) stock is a Buy with a HK$71.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H

Shanghai HeartCare Medical Technology Corporation Limited is a PRC-based medical device company specializing in neuro-interventional products, with a particular focus on technologies and devices for treating ischemic and hemorrhagic stroke as well as interventional access products. The company operates in the neurovascular medical technology industry, targeting the growing market for minimally invasive stroke therapies in China and abroad.

Average Trading Volume: 66,299

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.18B

For a thorough assessment of 6609 stock, go to TipRanks’ Stock Analysis page.